Evaluation of uncertainty parameters estimated by different population PK software and methods

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 34, Issue 3, 2007, Pages 289-311

  Dartois, Céline ^a,b   Lemenuel Diot, Annabelle ^c   Laveille, Christian ^d   Tranchand, Brigitte ^a,b,e   Tod, Michel ^a,f,g   Girard, Pascal ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d Exprimo NV   (Belgium)

^e CENTRE LÉON BÉRARD   (France)

^f Hôpital Cochin ^*  (France)

^g UNIVERSITÉ LYON 1   (France)

Author keywords

Estimation method; Non linear mixed effect model; Pharmaco kinetics; Standard error; Uncertainty

Indexed keywords

ANALYTIC METHOD; ANALYTICAL ERROR; ANALYTICAL PARAMETERS; ARTICLE; BAYES THEOREM; BOOTSTRAPPING; COMPARTMENT MODEL; COMPUTER PROGRAM; CONFIDENCE INTERVAL; MATHEMATICAL COMPUTING; NONLINEAR SYSTEM; PERFORMANCE MEASUREMENT SYSTEM; POPULATION MODEL; PRIORITY JOURNAL; RANDOMIZATION; SIMULATION;

EID: 34249867397     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-006-9046-9     Document Type: Article

References (52)

1. Meibohm B. and Derendorf H. (2002) Pharmacokinetic/pharmacodynamic studies in drug product development. J. Pharm. Sci. 91:18-31
2. Sheiner L.B. and Steimer J.L. (2000) Pharmacokinetic/pharmacodynamic modeling in drug development. Annu. Rev. Pharmacol. Toxicol. 40:67-95
3. Evans W.E., Relling M.V., Rodman J.H., Crom W.R., Boyett J.M., Pui C.H. (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med. 338:499-505
4. Jelliffe R.W. (1987) Clinical applications of pharmacokinetics and adaptive control. IEEE Trans. Biomed. Eng. 34:624-632
5. Jelliffe R. W., A. Schumitzky, Van Liu G. M. M., Hu L., Maire P., Gomis P., Barbaut X., and Tahani B. (1993) Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther. Drug Monit. 15:380-393.
6. Sheiner L.B., Rosenberg B., Melmon K.L. (1972) Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput. Biomed. Res. 5:411-459
7. Karlsson M.O. and Sheiner L.B. (1993) The importance of modeling interoccasion variability in population pharmacokinetic analyses. J. Pharmacokinet. Biopharm. 21:735-750
8. S. Retout, S. Duffull, and F. Mentré. (2001) Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput. Methods Programs Biomed. 65:141-151.
9. Retout S. and Mentré F. (2003) Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics. J. Biopharm. Stat. 13:209-227
10. Yano Y., Beal S.L., and Sheiner L.B. (2001) Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J. Pharmacokinet. Pharmacodyn. 28:171-192
11. Food and Drug Administration. Guidance for industry - Population pharmacokinetics. Available from: http://www.fda.gov/cder/guidance/1852fnl.pdf. Last Accessed: July 4 2006.
12. F. Mentré and M. E. Ebelin. Validation of population pharmacokinetic/pharmacodynamic analyses: review of proposed approaches. In: COST B1. European cooperation in the field of scientific and technical research. The population approach: measuring and managing variability in response, concentration and dose, L. Aarons, L. P. Balant, M. Danhof, M. Gex-Fabry, U. Gundert-Remy, M. Karlsson, F. Mentre, P. Morselli, M. Rowland, J. L. Steimer, S. Vozeh, and F. Rombout, eds. pp. 148-160, Office for official publications of the European Communities, Brussels.
13. Ette E.I., Williams P.J., Kim Y.H., Lane J.R., Liu M.J., and Capparelli E.V. (2003) Model appropriateness and population pharmacokinetic modeling. J. Clin. Pharmacol. 43:610-623
14. Tod M. and Rocchisani J.M. (1996) Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria. Comput. Methods Programs Biomed. 50:13-22
15. Tod M. and Rocchisani J.M. (1997) Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics. J Pharmacokinet. Biopharm. 25:515-537
16. Matthews I., Kirkpatrick C., and Holford N. (2004) Quantitative justification for target concentration intervention-parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br. J. Clin. Pharmacol. 58:8-19
17. Bonate P.L., Craig A., Gaynon P., Gandhi V., Jeha S., Kadota R., Lam G.N., Plunkett W., Razzouk B., Rytting M., Steinherz P., and Weitman S. (2004) Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J. Clin. Pharmacol. 44:1309-1322
18. Jolling K., Ruixo J.J., Hemeryck A., Piotrovskij V., and Greway T. (2004) Population pharmacokinetic analysis of pegylated human erythropoietin in rats. J. Pharm. Sci. 93:3027-3038
19. Bruno R., Washington C. B., Lu J. F., Lieberman G., Banken L., and Klein P. (2005) Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer. Cancer Chemother. Pharmacol.
20. Lindbom L., Pihlgren P., and Jonsson E.N. (2005) PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Programs Biomed. 79:241-257
21. Beal S. L. and Sheiner L. B. (1989). NONMEM User's Guide - Part I. Users Basic Guide. University of California, San Francisco
22. Pinheiro J. C. and Bates D. M. Mixed-Effects Models in S and S-PLUS. Springer-Verlag, New York, 2001.
23. Delyon B., Lavielle M., Moulines E. (1999) Convergence of a stochastic approximation version of the EM algorithm. Ann. Stat. 27:94-128
24. Kuhn E. and Lavielle M. (2004) Coupling a stochastic approximation version of EM with a MCMC procedure. ESAIM P&S: 115-131
25. D. Spiegelhalter, A. Thomas, N. Best, and D. J. Lunn. WinBUGS User Manual Version 1.4. Available from: http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/ contents.shtml. Last Accessed: July 4 2006.
26. Ette E.I. (1996) Comparing non-hierarchical models: application to non-linear mixed effects modeling. Comput. Biol. Med. 26:505-512
27. M. Davidian and D. M. Giltinan. Nonlinear Models for Repeated Measurement Data. Chapman & Hall, London, 1995.
28. Davidian M. and Giltinan D.M. (2003) Nonlinear Models for Repeated Measurement Data: An Overview and Update. J. Agr. Biol. Envir. St. 8:387-419
29. Lindstrom M.J. and Bates D.M. (1990) Nonlinear mixed effects models for repeated measures data. Biometrics 46:673-687
30. J. I. Myung and D. J. Navarro. Information matrix. In: Encyclopedia of behavioral Statistics, B. Everitt and D. Howel, eds., 2004.
31. Retout S., Mentré F., Bruno R. (2002) Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. Stat. Med. 21:2623-2639
32. S. L. Beal and L. B. Sheiner. NONMEM User's Guide - Part II. Users Supplemental Guide. University of California, San Francisco, 1988.
33. White H. (1982) Maximum likelihood estimation of misspecified model. Econometrica 50:1-25
34. Kuhn E. and Lavielle M. (2005) Maximum likelihood estimation in nonlinear mixed effects model. Comput. Stat. Data Anal. 49:1020-1038
35. B. Efron and R. Tibshirani. An Introduction to the Bootstrap. Chapman & Hall, New York, 1993.
36. Ette E.I. (1997) Stability and performance of a population pharmacokinetic model. J. Clin. Pharmacol. 37:486-495
37. Das S. and Krishen A. (1999) Some bootstrap methods in nonlinear mixed-effect models. J. Stat. Plan. Inference 75:237-245
38. Wu C.F.J. (2006) Comment on jackknife, bootstrap and resampling methods in regression analysis. Ann. Stat. 14:1261-1350
39. Gelman A., Carlin J. B., Stern H. S., and Rubin D. B. Bayesian Data Analysis, 2nd ed. Chapman & Hall, London, 2004.
40. Gelman A. and Rubin D.B. (1992) Inference from iterative simulation using multiple sequences (with discussion). Stat. Sci. 7:457-511
41. Brooks S.P. and Gelman A. (1998) Alternative methods for monitoring convergence of iterative simulations. J. Comput. Graph. Stat. 7:434-455
42. Best N.G., Tan K.K., Gilks W.R., and Spiegelhalter D.J. (1995) Estimation of population pharmacokinetics using the Gibbs sampler. J. Pharmacokinet. Biopharm. 23:407-435
43. Lunn D.J., Best N., Thomas A., Wakefield J., and Spiegelhalter D. (2002) Bayesian analysis of population PK/PD models: general concepts and software. J. Pharmacokinet. Pharmacodyn 29:271-307
44. Pouillot R., Albert I., Cornu M., and Denis J.-B. (2003) Estimation of uncertainty and variability in bacterial growth using Bayesian inference. Application to Listeria monocytogenes. Int. J. Food. Microbiol. 81:87-104
45. Roe D.J. (1997) Comparison of population pharmacokinetic modeling methods using simulated data: results from the population modeling workgroup. Stat. Med. 16:1241-1262
46. A. J. Boeckmann, L. Sheiner, and S. L. Beal. NONMEM User's Guide - Part VIII. Help Guide. University of California, San Francisco, 1996.
47. Tod M., Mentré F., Merlé Y., and Mallet A. (1998) Robust optimal design for the estimation of hyperparameters in population pharmacokinetics. J. Pharmacokinet. Biopharm. 26:689-716
48. M. Tod, F. Mentré, Y. Merlé, and A. Mallet. Introduction to POPOS (optimization of sampling times for population parameter estimation in pharmacokinetics). In POPOS 1.0. 2000, pp. 4-5.
49. Gisleskog P.O., Karlsson M.O., Beal S.L. (2005) Use of prior information to stabilize a population data analysis. J. Pharmacokinet. Biopharm. 29:473-505
50. White D.B., Walawander C.A., Tung Y., and Grasela T.H. (1991) An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis. J. Pharmacokinet. Biopharm. 19:87-112
51. Laird N.M. and Louis T.A. (1987) Empirical Bayes confidence intervals based on bootstrap samples. J. Am. Stat. Assoc. 32:739-757
52. Wade J.R., Kelman A.W., Howie C.A. and Whiting B. (1993) Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J. Pharmacokinet. Biopharm. 21:209-222